1998
DOI: 10.1016/s0960-894x(98)00286-8
|View full text |Cite
|
Sign up to set email alerts
|

Novel modified tripeptide inhibitors of α4β7 mediated lymphoid cell adhesion to MAdCAM-1

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

1
13
0

Year Published

1998
1998
2019
2019

Publication Types

Select...
5
2

Relationship

0
7

Authors

Journals

citations
Cited by 15 publications
(14 citation statements)
references
References 12 publications
1
13
0
Order By: Relevance
“…Although these studies support the integrin selectivity data for BIO7662, the separation under activating conditions between the IC 50 of BIO7662 in the adhesion assay (1 M) and the amount added to prevent ␣ 4 ␤ 1 binding, 100 nM, was not as great as was predicted from the MAdCAM-Ig binding study (Table 1), and consequently binding of BIO7662 to ␣ 4 ␤ 7 is likely to have accounted for the reduction in the counts bound for 35 S-compound 1. The RPMI-8866 cell line has been widely used in binding assays to identify ␣ 4 ␤ 7 antagonists (Carson et al, 1997;Shroff et al, 1998;Martin et al, 1999;Harriman et al, 2000). We provide the first evidence that low levels of unactivated ␣ 4 ␤ 1 expressed on RPMI-8866 cells are capable of binding to a small molecule antagonist, such as 35 S-compound 1, and we demonstrate that unactivated ␣ 4 ␤ 7 on a variety of cell lines does not bind 35 S-compound 1.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Although these studies support the integrin selectivity data for BIO7662, the separation under activating conditions between the IC 50 of BIO7662 in the adhesion assay (1 M) and the amount added to prevent ␣ 4 ␤ 1 binding, 100 nM, was not as great as was predicted from the MAdCAM-Ig binding study (Table 1), and consequently binding of BIO7662 to ␣ 4 ␤ 7 is likely to have accounted for the reduction in the counts bound for 35 S-compound 1. The RPMI-8866 cell line has been widely used in binding assays to identify ␣ 4 ␤ 7 antagonists (Carson et al, 1997;Shroff et al, 1998;Martin et al, 1999;Harriman et al, 2000). We provide the first evidence that low levels of unactivated ␣ 4 ␤ 1 expressed on RPMI-8866 cells are capable of binding to a small molecule antagonist, such as 35 S-compound 1, and we demonstrate that unactivated ␣ 4 ␤ 7 on a variety of cell lines does not bind 35 S-compound 1.…”
Section: Discussionmentioning
confidence: 99%
“…Small molecule antagonists of ␣ 4 ␤ 7 that mimic the LDT motif have been described that block the binding of ␣ 4 ␤ 7 -expressing cells to MAdCAM-Ig in the presence of Mn 2ϩ (Carson et al, 1997;Shroff et al, 1998;Martin et al, 1999;Harriman et al, 2000;Egger et al, 2002). Similarly, antagonists of ␣ 4 ␤ 1 have been reported to block binding of Mn 2ϩ -activated (Jackson et al, 1997;Vanderslice et al, 1997;Lin et al, 1998;Hagmann et al, 2001;Muller et al, 2001) and unactivated ␣ 4 ␤ 1 (Chen et al, 1999) to ligand in vitro.…”
mentioning
confidence: 99%
“…The potential value of this therapy has already been shown with antibodies in animal models of colitis 5. 6 Recently, we and others reported the synthesis of peptidic α4β7‐integrin antagonists that contain the Leu‐Asp‐Thr (LDT) recognition sequence for α4β7‐integrins 710. In our previous work we showed that the amide bond between Thr 4 and Asp 5 in the cyclic peptide cyclo ‐(Phe 1 ‐Leu 2 ‐Asp 3 ‐Thr 4 ‐Asp 5 ‐ D ‐Pro 6 ) was not essential.…”
Section: Specific Effects Of Peptidomimetics (1 Mg Ml−1) On α4β7‐ Andmentioning
confidence: 99%
“…). Based on these results and on the results of Shroff et al,9, 10 we developed a library illustrated in Figure 1. Four different building blocks A , B , C, and D were used.…”
Section: Specific Effects Of Peptidomimetics (1 Mg Ml−1) On α4β7‐ Andmentioning
confidence: 99%
“…Small molecule antagonists of ␣ 4 ␤ 7 that block the static adhesion of human ␣ 4 ␤ 7 -expressing cells to the CS-1 subdomain of human fibronectin, human VCAMIg, human MAdCAM-Ig, or murine MAdCAM-Ig have been described previously (Shroff et al, 1996(Shroff et al, , 1998Carson et al, 1997;Harriman et al, 1999;Martin et al, 1999). The ability of ␣ 4 ␤ 7 antagonists to block the binding of murine ␣ 4 ␤ 7 -expressing cells to soluble murine MAdCAM-Ig under static conditions has also been reported , but the ability of compounds to block ligand binding under in vitro or in vivo shear flow conditions has not been examined.…”
mentioning
confidence: 99%